Form 8-K - Current report:
SEC Accession No. 0001140361-25-032012
Filing Date
2025-08-20
Accepted
2025-08-20 07:11:02
Documents
14
Period of Report
2025-08-20
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20054253_8k.htm   iXBRL 8-K 28964
2 EXHIBIT 99.1 ef20054253_ex99-1.htm EX-99.1 21015
6 image00001.jpg GRAPHIC 4294
  Complete submission text file 0001140361-25-032012.txt   190163

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rckt-20250820.xsd EX-101.SCH 3877
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rckt-20250820_lab.xml EX-101.LAB 21966
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rckt-20250820_pre.xml EX-101.PRE 16052
16 EXTRACTED XBRL INSTANCE DOCUMENT ef20054253_8k_htm.xml XML 4057
Mailing Address 350 FIFTH AVENUE SUITE 7530 NEW YORK NY 10118
Business Address 350 FIFTH AVENUE SUITE 7530 NEW YORK NY 10118 646-440-9100
ROCKET PHARMACEUTICALS, INC. (Filer) CIK: 0001281895 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)